CliffBio
biologic

Rituxan

rituximab

Loss of exclusivityNovember 2009projected — 12-year biologic exclusivity estimate
CompanyGenentech →See this company's full patent-cliff portfolio

Drug detail

Brand nameRituxan
Active ingredientrituximab
Strength100MG/10ML (10MG/ML)
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalNovember 1997
Marketing statusRx

More from Genentech

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Rituxan patent cliff — loss of exclusivity November 2009 | CliffBio